B

BioNote Inc
KRX:377740

Watchlist Manager
BioNote Inc
KRX:377740
Watchlist
Price: 4 600 KRW -2.13% Market Closed
Market Cap: 469.1B KRW
Have any thoughts about
BioNote Inc?
Write Note

BioNote Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BioNote Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
B
BioNote Inc
KRX:377740
Current Portion of Long-Term Debt
â‚©1.3B
CAGR 3-Years
113%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Current Portion of Long-Term Debt
â‚©175.7B
CAGR 3-Years
36%
CAGR 5-Years
15%
CAGR 10-Years
-2%
SK Bioscience Co Ltd
KRX:302440
Current Portion of Long-Term Debt
â‚©8.1B
CAGR 3-Years
-14%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Current Portion of Long-Term Debt
â‚©2.7B
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Current Portion of Long-Term Debt
â‚©33.7B
CAGR 3-Years
93%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Current Portion of Long-Term Debt
â‚©88.9B
CAGR 3-Years
11%
CAGR 5-Years
295%
CAGR 10-Years
N/A
No Stocks Found

BioNote Inc
Glance View

Market Cap
469.5B KRW
Industry
Biotechnology

BioNote, Inc. develops veterinary diagnostic composition. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2022-12-22. The firm is engaged in the manufacture and sale of rapid diagnostic kits for humans, diagnosis raw materials such as antigens, antibody cell lines, standards, enzymes and others as well as semi-finished products. The firm is also engaged in the manufacture and sale of rapid immunochemical diagnosis, enzyme immune rebound protein, immunochemical fluorescence diagnosis and other products used for animals.

Intrinsic Value
6 138.02 KRW
Undervaluation 25%
Intrinsic Value
Price
B

See Also

What is BioNote Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
1.3B KRW

Based on the financial report for Dec 31, 2023, BioNote Inc's Current Portion of Long-Term Debt amounts to 1.3B KRW.

What is BioNote Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
113%

Over the last year, the Current Portion of Long-Term Debt growth was 185%. The average annual Current Portion of Long-Term Debt growth rates for BioNote Inc have been 113% over the past three years .

Back to Top